Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
A Systematic Review and Meta-Analysis: Memantine Augmentation in Moderate to Severe Obsessive-Compulsive Disorder Publisher Pubmed



Modarresi A1 ; Chaibakhsh S1, 2 ; Koulaeinejad N3 ; Koupaei SR4
Authors

Source: Psychiatry Research Published:2019


Abstract

A considerable proportion of obsessive-compulsive disorder (OCD) patients receiving first-line pharmacological therapy, fail to fully respond to treatment and continue to exhibit significant symptoms. In this systematic review, we evaluate the efficacy of memantine, as a glutamate-modulating agent, in moderate to severe OCD. Single and double blinded as well as open-label trials of memantine augmentation in adults with OCD were considered. Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores were the primary outcome measure. The electronic databases of PubMed, Scopus, Embase and Google Scholar were searched for relevant trials using keywords ‘obsessive-compulsive disorder OR OCD’ AND ‘memantine’. The meta-analysis of eight studies involving 125 OCD subjects receiving memantine augmentation exhibited a significant overall mean reduction of 11.73 points in Y-BOCS scores. The categorical analysis of treatment response (a minimum of 35% reduction in Y-BOCS) in four double-blind placebo-controlled studies indicated that OCD patients receiving memantine augmentation were 3.61 times more likely to respond to treatment than those receiving placebo. We found that 20 mg/day memantine augmentation to first-line pharmacological treatment for a period of at least 8 weeks is a safe and effective intervention for moderate to severe OCD. © 2019
Related Docs
View other Related Docs
1. Memantine Augmentation Improves Symptoms in Serotonin Reuptake Inhibitor-Refractory Obsessive-Compulsive Disorder: A Randomized Controlled Trial, Pharmacopsychiatry (2018)
2. L-Carnosine As an Adjuvant to Fluvoxamine in Treatment of Obsessive Compulsive Disorder: A Randomized Double-Blind Study, Human Psychopharmacology (2017)
3. Minocycline Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2016)
Experts (# of related papers)
View all Related Experts
Shahin Akhondzadeh Basti (11)
Farzin Rezaei (3)
Other Related Docs
4. N-Acetylcysteine Augmentation Therapy for Moderate-To-Severe Obsessive-Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Clinical Pharmacy and Therapeutics (2016)
5. Riluzole in Augmentation of Fluvoxamine for Moderate to Severe Obsessive–Compulsive Disorder: Randomized, Double-Blind, Placebo-Controlled Study, Psychiatry and Clinical Neurosciences (2016)
6. Amantadine As Adjuvant Therapy in the Treatment of Moderate to Severe Obsessive–Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, Psychiatry and Clinical Neurosciences (2019)
7. L-Theanine Combination Therapy With Fluvoxamine in Moderate-To-Severe Obsessive–Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Psychiatry and Clinical Neurosciences (2023)
8. Repetitive Transcranial Magnetic Stimulation (Rtms) Improves Symptoms and Reduces Clinical Illness in Patients Suffering From Ocd - Results From a Single-Blind, Randomized Clinical Trial With Sham Cross-Over Condition, Journal of Psychiatric Research (2015)
9. Glutamatergic Medications As Adjunctive Therapy for Moderate to Severe Obsessive-Compulsive Disorder in Adults: A Systematic Review and Meta-Analysis, BMC Pharmacology and Toxicology (2021)
10. Comparison of Saffron and Fluvoxamine in the Treatment of Mild to Moderate Obsessive-Compulsive Disorder: A Double Blind, Randomized Clinical Trial, Iranian Journal of Psychiatry (2017)
11. The Safety and Efficacy of Transcranial Direct Current Stimulation As Add-On Therapy to Fluoxetine in Obsessive-Compulsive Disorder: A Randomized, Double-Blind, Sham-Controlled, Clinical Trial, BMC Psychiatry (2020)
12. Correlations Between Single Nucleotide Polymorphisms in Obsessive-Compulsive Disorder With the Clinical Features or Response to Therapy, Journal of Psychiatric Research (2023)
13. Fluvoxamine Combination Therapy With Tropisetron for Obsessive-Compulsive Disorder Patients: A Placebo-Controlled, Randomized Clinical Trial, Journal of Psychopharmacology (2019)
14. A Comparative, Single-Blind, Randomized Study on Quetiapine and Aripiperazole Augmentation in Treatment of Selective Serotonin Reuptake Inhibitor Refractory Obsessive-Compulsive Disorder, Canadian Journal of Physiology and Pharmacology (2020)
15. The Efficacy of Aripiprazole Versus Risperidone As Augmentation Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: A Double Blind Clinical Trial, Iranian Red Crescent Medical Journal (2018)
16. Efficacy of N-Acetylcysteine Augmentation on Obsessive Compulsive Disorder: A Multicenter Randomized Double Blind Placebo Controlled Clinical Trial, Iranian Journal of Psychiatry (2017)
17. 5-Hydroxytryptophan As Adjuvant Therapy in Treatment of Moderate to Severe Obsessive-Compulsive Disorder: A Double-Blind Randomized Trial With Placebo Control, International Clinical Psychopharmacology (2020)
18. Reboxetine Combination Therapy With Fluoxetine in Moderate to Severe Obsessive-Compulsive Disorder: A Placebo-Controlled, Double-Blind, Randomized Trial, Clinical Neuropharmacology (2023)
19. The Prevalence and Clinical Features of Amphetamine-Induced Obsessive Compulsive Disorder, Drug and Alcohol Dependence (2016)
20. Repetitive Transcranial Magnetic Stimulation Improved Symptoms of Obsessive-Compulsive Disorder, But Also Cognitive Performance: Results From a Randomized Clinical Trial With a Cross-Over Design and Sham Condition, Neuropsychobiology (2016)